Related Experiment Video

Updated: Jun 16, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

[Homocysteine and cognitive impairment in Parkinson's disease]

José Javier Martín-Fernández1, Rafael Carles-Díes, Francisco Cañizares

  • 1Servicio de Neurología, Hospital Universitario Virgen de la Arrixaca, El Palmar, Espana. josej.martin@carm.es

Revista De Neurologia
|February 11, 2010
PubMed

Insights

Parkinson's disease patients on levodopa treatment show elevated homocysteine (Hc) levels, particularly those with cognitive impairment. This suggests a link between Hc, levodopa, and cognitive decline in PD.

Area of Science:

  • Neurology
  • Biochemistry

Context:

  • Homocysteine (Hc) is linked to vascular diseases and cognitive impairment.
  • Parkinson's disease (PD) patients on levodopa may experience increased Hc levels, potentially worsening cognitive function.

Purpose:

  • Confirm elevated Hc levels in levodopa-treated PD patients.
  • Investigate relationships between Hc, vitamin B12, and folic acid.
  • Explore the link between these factors and cognitive function in PD.

Summary:

  • This study included 58 PD patients (45 on levodopa), measuring Hc, vitamin B12, and folic acid levels.
  • Higher Hc levels were observed in patients taking levodopa, correlating negatively with vitamin B12 and folic acid in men.
  • Elevated Hc was significantly associated with cognitive impairment in PD patients.

Impact:

  • Confirms elevated Hc in levodopa-treated PD patients, especially those with cognitive deficits.
  • Highlights the potential role of Hc in levodopa-induced cognitive impairment in Parkinson's disease.
Abstract

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...